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Myocardial infarction is responsible for about 
one third of heart failure cases (1–3). It is de-
fi  ned as the loss of myocardial tissue that is re-
placed by scar tissue (4, 5). The formation of 
scar tissue is not only one of the most impor-
tant factors compromising the pump function 
of the failing heart, but it is also an important 
risk factor for ventricular arrhythmias because 
it constitutes anatomical conduction barriers 
that cause electrical reentrant circuits. Ventric-
ular tachyarrhythmias are the main cause for 
sudden death in heart failure patients (4–6). 
Therefore, new approaches for the therapy of 
heart failure should not only improve hemody-
namic function, but they should also aim at a 
reduction of the vulnerability to arrhythmias.
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Initial preclinical and clinical trials have dem-
onstrated that the transfer of BM-derived stem 
and precursor cells into the infarcted myocardium 
can improve left ventricular systolic function 
(7–9). Similar results were obtained by the appli-
cation of the cytokine granulocyte colony-stim-
ulating factor (G-CSF), alone or in combination 
with stem cell factor (SCF), which is known to 
mobilize BM-derived cells (10–14). The publica-
tions of Orlic et al. (10, 15, 16) suggest that the 
benefi  cial eff  ects of these therapies are due to a 
signifi  cant degree of structural regeneration of 
the infarcted hearts by transdiff  erentiation of the 
immigrated BM-derived cells to cardiomyocytes. 
In contrast, others (17–19) were unable to re-
produce these results. However, recent data by 
  Gnecchi et al. (20) indicate that paracrine (hu-
moral) factors secreted by BM-derived cells 
promote cardiomyocyte survival. Recently, a 
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Granulocyte colony-stimulating factor (G-CSF), alone or in combination with stem cell 
factor (SCF), can improve hemodynamic cardiac function after myocardial infarction. Apart 
from impairing the pump function, myocardial infarction causes an enhanced vulnerability 
to ventricular arrhythmias. Therefore, we investigated the electrophysiological effects of 
G-CSF/SCF and the underlying cellular events in a murine infarction model.
G-CSF/SCF improved cardiac output after myocardial infarction. Although G-CSF/SCF 
led to a twofold increased, potentially proarrhythmic homing of bone marrow (BM)-derived 
cells to the area of infarction, <1% of these cells adopted a cardial phenotype. Inducibility 
of ventricular tachycardias during programmed stimulation was reduced 5 wk after G-CSF/
SCF treatment. G-CSF/SCF increased cardiomyocyte diameter, arteriogenesis, and expres-
sion of connexin43 in the border zone of the infarction. An enhanced expression of the 
G-CSF receptor demonstrated in cardiomyocytes and other cell types of the infarcted 
myocardium indicates a sensitization of the heart to direct infl  uences of this cytokine. In 
addition to paracrine effects potentially caused by the increased homing of BM-derived 
cells, these might contribute to the therapeutic effects of G-CSF.
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new aspect was added by the work of Harada et al. (14), who 
identifi  ed direct eff  ects of G-CSF on car  diomyocytes in vitro.
However, the mere increase of BM-derived cells in the 
infarcted heart by cytokine treatment as well as their poten-
tial transdiff  erentiation into noncardiomyocytes or even 
cardiomyocytes might carry a risk for pro-arrhythmia. The 
transfer of skeletal myoblasts into failing hearts has been 
shown to provoke ventricular tachycardias in patients (21), 
and certain types of cardiomyocytes derived from in vitro–
diff  erentiated embryonic stem cells exhibited prolonged ac-
tion potential durations, afterdepolarizations, and a potential 
for arrhythmogenesis (22). On the other hand, reducing the 
infarct size has the potential to reduce the risk of ventricular 
arrhythmias   after myocardial infarction. Therefore, the aim 
of this study was to systematically evaluate the midterm 
electrophysiological eff  ects of G-CSF/SCF treatment on 
hearts subjected to myocardial infarction, and to reveal cel-
lular changes potentially underlying the observed physio-
logical alterations.
RESULTS
G-CSF/SCF promotes the homing of enhanced green 
fl  uorescent protein (EGFP)+ cells in the infarcted left 
ventricle of mice
The homing of BM-derived cells to the infarcted myocar-
dium on the one hand might contribute to the benefi  cial ef-
fects of G-CSF/SCF by paracrine mechanisms. On the other 
hand, it might constitute the cellular basis for an enhanced 
susceptibility to arrhythmia. Because of these notions, the 
homing of BM-derived cells was comparatively analyzed in 
G-CSF/SCF-treated and untreated infarcted hearts.
EGFP-transgenic donor mice were used for BM trans-
plantation (BMT) into irradiated recipient animals before these 
were subjected to infarction and G-CSF/SCF treatment. As ex-
pected, ligation of the left anterior descending coronary artery 
(LAD) caused anterior myocardial infarction as evident by re-
placement of myocardium with fi  brotic scar tissue 5 wk after 
the infarction (Fig. 1 A). Morphometric analysis of the hearts 
of 15 BMT animals (4 G-CSF/SCF treated and 11 untreated) 
killed 5 wk after induction of myocardial infarction identi-
fi  ed EGFP+ (BM-derived) cells predominantly in the area of 
myocardial infarction and its border zone (Fig. 1 B). Further-
more, G-CSF/SCF led to a twofold increase of homing of 
EGFP+ cells to the infarcted area and the border zone of 
myocardial infarction (P < 0.05 for G-CSF/SCF vs. con-
trols). In agreement with this fi  nding, G-CSF/SCF led to a 
threefold rise in white blood cell concentration in the periph-
eral blood, accompanied by a doubling of the neutrophil pro-
portion in splenectomized mice (not depicted). In 10 BMT 
animals not subjected to infarction (fi  ve G-CSF/SCF treated 
and fi  ve untreated), the accumulation of EGFP+ cells 5 wk 
after G-CSF/SCF treatment was 4–6-fold lower than in the 
non-infarcted myocardial tissue of animals with myocardial 
infarction (Fig. 1 B).
98–99% of EGFP+ cells in the myocardium were white 
blood cells as evident by coimmunolocalization of CD45 
Figure 1.  Homing of BM-derived cells in the infarcted myocar-
dium. (A) Histological reconstruction of a short axis cut of the left ven-
tricle after myocardial infarction seen in Goldner’s Trichrom stain. The 
infarcted area (top left quadrant of the section, arrows) is characterized 
by thinning of the left ventricular wall and replacement of myocardium 
with fi  brotic tissue (green) and infl  ammatory cells. A subendocardial layer 
of myocardium survived after myocardial infarction. LV, left ventricle; RV, 
right ventricle; S, septum. (B) Quantitative analysis of EGFP+ cells in the 
infarcted and non-infarcted regions as well as in the border zone of 
G-CSF/SCF-treated and untreated hearts 5 wk after induction of myocar-
dial infarction. Also, percentages of EGFP+ cells in the hearts of G-CSF/
SCF-treated and untreated EGFP BM chimeras not subjected to infarction 
are indicated. Asterisks above bars indicate statistically signifi  cant differ-
ences of percentages of EGFP+ cells between the border zone or area of 
infarction and non-infarcted areas of the same animals for controls or 
G-CSF/SCF mice (P < 0.05). Asterisks above parentheses indicate signifi  -
cant differences between the border zone or area of infarction of controls 
and G-CSF/SCF group. (C) Colocalization (right) of EGFP fl  uorescence (left) 
and CD45 immunofl  uorescence (middle) indicates that the majority of 
BM-derived cells are white blood cells. (D) Green fl  uorescent cardiomyo-
cytes (*) in the scar tissue of a G-CSF/SCF animal (D1) and the non-
  infarcted area of a non–G-CSF/SCF animal (D2) 5 wk after induction of 
myocardial infarction in recipients of EGFP-expressing BM. Intact cardio-
myocytes are labeled by immunofl  uorescence for troponin T using a red 
fl  uorochrome (Alexa Fluor 594). The green color represents the autofl  uo-
rescence of EGFP+ (BM-derived) cells.JEM VOL. 203, January 23, 2006  89
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(Fig. 1 C), regardless of location (infarcted vs. non-infarcted 
area), and protocol type (G-CSF/SCF vs. control). In >100 
sections from the hearts of G-CSF/SCF and control animals, 
only one troponin T+/EGFP+ cell with central nucleus, 
myofi  laments, and cross-striation (Fig. 1 D) was identifi  ed in 
an area of infarction. In the non-infarcted areas, troponin 
T+/EGFP+ cells were casually found (up to fi  ve cells per 
cross section).
G-CSF receptor (G-CSFR) is expressed in several cell types 
of the heart and is up-regulated by infarction
Because G-CSF and SCF were administered systemically, 
expression of the corresponding receptors was analyzed in 
the heart to fi   nd evidence for potential direct eff  ects  on 
myocardial tissue. G-CSFR expression was evaluated by im-
munofl  uorescence microscopy 1 d and 5 wk after induction 
of myocardial infarction as well as by quantitative real-time 
RT-PCR at six time points after infarction. 1 d after myo-
cardial infarction, prominent G-CSFR expression in the 
non-infarcted area was predominantly detected in small in-
terstitial and vascular cells (Fig. 2 A, 1), whereas in the in-
farcted area, cardiomyocytes also exhibited weak G-CSFR 
immunofl  uorescence (Fig. 2 A, 2). In contrast, 5 wk after 
induction of myocardial infarction, cardiomyocytes exhib-
ited marked G-CSFR expression both in the non-infarcted 
area and in the border zone (Fig. 2 A, 3 and 4). Cardiomyo-
cytes, immunopositive for G-CSFR, display a bright red co-
rona, indicating membrane localization of the receptor. 
Animals investigated 1 d after myocardial infarction were 
chimeras with EGFP-expressing BM (see Materials and 
methods). Because the small interstitial cells, immunoposi-
tive for G-CSFR, were not EGFP+, these cells were not of 
hematopoietic origin but were resident myocardial cells. In 
contrast to G-CSFR, the receptor for SCF (c-kit) was not 
Figure 2.  G-CSF/GCSFR expression in the myocardium. (A) G-CSFR 
expression 1 d (1 and 2) and 5 wk (3 and 4) after induction of myocardial 
infarction. Blue, DAPI-stained nuclei; bright green, EGFP emission; dark 
green, autofl  uorescence of cardiomyocytes; red, Cy3-labeled G-CSFR. 
Arrows indicate small interstitial cells. Right box in panel 1 indicates a 
G-CSFR+ vessel. Arrowheads in panel 3: Bright red corona, indicating 
membrane localization of the receptor. Immunopositive interstitial cells 
appear pink (arrows) because of their high nucleus/plasma ratio and the 
interference of blue DAPI emission (nucleus) and the red Cy3 emission of 
the G-CSFR label. (B) Expression of G-CSF mRNA and G-CSFR mRNA as 
determined by real-time RT-PCR at different time points after induction of 
myocardial infarction in the area of infarction and non-infarcted left ven-
tricular tissue of untreated animals. Left ventricular tissue of seven normal 
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detectable by immunofl  uorescence 5 wk after myocardial in-
farction (not depicted).
Real-time RT-PCR analysis of myocardial tissue of 
  untreated animals revealed an up-regulation of G-CSF and 
G-CSFR mRNA levels within the fi  rst 24 h after induction 
of myocardial infarction, which was more pronounced in 
the aff  ected tissue than in the non-infarcted area (Fig. 2 B).
G-CSF/SCF improves hemodynamic function
Myocardial infarction induced by LAD ligation led to re-
gional wall motion abnormalities of the anterior wall, re-
duced fractional shortening, and typical electrocardiogram 
(ECG) changes seen after anterior myocardial infarction in 
the mouse (Fig. 3, A and B). Infarction size was relatively 
homogeneous throughout the experiments and did not dif-
fer between G-CSF/SCF hearts and controls, neither in 
pathological measurements (Table I) nor in vivo, assessed 
by the akinetic area of the left ventricle on echocardiogra-
phy (G-CSF/SCF treated 5.4 ± 0.8 mm2 vs. controls 6.7 ± 
1.1 mm2; P = 0.39). Also, left ventricular contractility did 
not diff  er between G-CSF/SCF-treated mice and controls. 
It is worthy to note that fractional shortening showed a 
trend toward better function, and septal wall width border-
ing the area of myocardial infarction showed a trend to-
ward greater thickness in G-CSF/SCF mice. Despite the 
lack in infarct size reduction, cardiac output was signifi  -
cantly increased in G-CSF/SCF mice compared with con-
trols (Fig. 3 C).
G-CSF/SCF does not provoke afterdepolarizations and 
spontaneous ventricular tachycardias in the intact heart
Based on reports of proarrhythmic eff  ects provoked by the 
transplantation of skeletal myoblasts (21), the proarrhythmic 
risk of the increased homing of BM-derived cells was as-
sessed by observing spontaneous ventricular rhythm after 
atrioventricular nodal block (23–25). This protocol did not 
provoke more spontaneous arrhythmias in G-CSF/SCF-
treated hearts compared with controls (7 out of 25 G-CSF/
SCF-treated hearts with spontaneous arrhythmias vs. 7 out 
of 26 controls; P = NS). Furthermore, ventricular action 
potential durations were shorter in G-CSF/SCF mouse 
hearts when pacing rates were high, whereas action potential 
Figure 3.  Surface ECG and echocardiographic examination of left 
ventricular function 5 wk after experimental infarction (A and B) 
and hemodynamic characterization of G-CSF/SCF-treated hearts 
compared with controls (C). (A) 12-lead surface ECGs recorded before 
(left panels, control) and 3 wk after infarction (right panels, infarction). The 
typical signs of infarction, loss of R waves in the Einthoven leads and per-
sistent ST segment elevation suggestive of anterior left ventricular dyski-
nesia, are present. (B) Echocardiographic examination before and 3 wk 
after experimental myocardial infarction in short axis (SAX, middle panels, 
orientation similar to the histological cut depicted in B) and long axis 
views (LAX, right panels) recorded during diastole (top panels) and systole 
(bottom panels). Arrows indicate the hypokinetic area in the systolic pic-
tures. (C) Comparative analysis of hemodynamic functions of G-CSF/SCF-
treated and untreated hearts. A statistically signifi  cant difference was 
observed for cardiac output (left). Septal wall width bordering the area of 
myocardial infarction displayed a trend toward greater thickness (middle), 
and fractional shortening (basal left ventricular M mode) showed a trend 
toward better function (right). For the following parameters no differences 
between G-CSF/SCF and control could be assessed: heart rate during echo-
cardiography: aortic Doppler velocity and left ventricular ejection time; 
basal left ventricular M mode: posterior wall width, left ventricular end-
diastolic diameter and left ventricular endsystolic diameter; mid-left ven-
tricular M mode: septal wall width, left ventricular enddiastolic diameter, 
left ventricular endsystolic diameter, and fractional shortening.JEM VOL. 203, January 23, 2006  91
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durations were not diff  erent between groups during long pacing 
cycle lengths (Table II).
G-CSF/SCF reduces inducibility of ventricular arrhythmias 
and increases connexin43 expression
Ventricular arrhythmias after myocardial infarction are often 
a result of conduction slowing in the border zone of the in-
farcted myocardium and associated with decreased intercel-
lular connections in this region (26). Programmed stimulation, 
the best assay to provoke such reentrant arrhythmias, pro-
voked less ventricular tachycardias in G-CSF/SCF-treated 
mice when either a single premature extra stimulus (Fig. 4 A, 
top) or two consecutive premature stimuli (Fig. 4 A, bottom) 
were applied (Fig. 4 B). As expected, a reduction of con-
nexin43 expression (90% reduction) was found in the border 
zone of the infarction (Fig. 4 C and Videos S1–S4, available 
at http://www.jem.org/cgi/content/full/jem.20051151/DC1), 
consistent with conduction slowing, the hallmark of in-
ducible ventricular arrhythmias after myocardial infarction. 
G-CSF/SCF-treated hearts, in contrast, had markedly higher 
connexin43 levels in the border zone of the infarction when 
compared with untreated controls (25% of normal con-
nexin43 levels; Fig. 4 C and Videos S1–S4).
G-CSF/SCF increases arteriogenesis and cardiomyocyte 
hypertrophy in the border zone of infarction
G-CSF/SCF enhanced arterialization in the border zone of 
myocardial infarction as indicated by an increased number of 
vessels per fi  eld of view (Fig. 5 A). However, concordant 
with increased arteriogenesis, the mean vessel diameter was 
not aff   ected. Cardiomyocyte hypertrophy was more pro-
nounced in the border zone of the infarction after G-CSF/
SCF treatment (Fig. 5 B).
DISCUSSION
Main fi  ndings
G-CSF/SCF treatment increased the homing of BM-derived 
cells (mainly white blood cells) into the infarcted myocar-
dium twofold. In addition, up-regulation of G-CSFR ex-
pression in the infarcted myocardium suggests a sensitization 
for direct eff  ects of the cytokine. G-CSF/SCF increased car-
diac output regardless of infarction size and integration of 
BM-derived cells into the myocardium. G-CSF/SCF re-
duced the inducibility of ventricular arrhythmias. This anti-
arrhythmic eff  ect can be attributed to an increased expression 
of connexin43 in cardiomyocytes in the border zone of the 
infarction. Although provocation of afterdepolarizations was 
a specifi  c aim of this study, there was no tendency for spon-
taneous arrhythmias or afterdepolarizations after G-CSF/
SCF treatment. The observed physiological eff  ects of cyto-
kine treatment were associated with cardiomyocyte hyper-
trophy and an enhanced arterialization in the border zone of 
the infarction.
Primary mechanisms of G-CSF/SCF effects
G-CSF/SCF treatment resulted in an increased homing of 
BM-derived cells (mainly white blood cells) into the in-
farcted myocardium and its border zone. In agreement with 
Murry et al. (17), Balsam et al. (18), and Nygren et al. (19), 
because a signifi  cant degree of transdiff  erentiation was not 
observed, this allows us to speculate that the observed thera-
peutic eff  ects may be due to the secretion of stimulatory 
  factors by white blood cells. However, the debate as to how 
G-CSF/SCF-based cardiac regenerative therapies improve 
cardiac function (10, 15–16), and whether transdiff  erentia-
tion of BM-derived cells is the underlying mechanism of 
myocardial regeneration (27, 28), has recently been extended 
by Harada et al. (14). Their results indicate a signifi  cant sur-
vival-promoting eff  ect of G-CSF treatment on cardiomyo-
cytes and endothelial cells that prevented left ventricular 
remodeling after myocardial infarction, suggesting that 
G-CSF may directly act on cardiomyocytes and endothelial 
cells. However, in contrast to Orlic et al. (10) and our work, 
they did not use splenectomized mice for their experiments. 
Diff  erences in neutrophil accumulation in the blood between 
splenectomized and nonsplenectomized mice might explain 
why they were unable to identify diff  erences between the 
homing of BM-derived cells in G-CSF–treated and control 
hearts. Although the threefold rise in white blood cell count 
in peripheral blood measured in our G-CSF/SCF–treated 
Table II.  Electrophysiology—ventricular action potential 
durations at 90% repolarization (APD90) for different pacing 
rate lengths in mice treated with G-CSF/SCF or placebo 
(controls)
APD90 G-CSF/SCF Controls
at 100 ms 31.1 ± 1.2 ms 35.6 ± 0.7 msa
at 120 ms 33.9 ± 1.5 ms 35.8 ± 1.0 ms
at 140 ms 38.8 ± 1.4 ms 36.2 ± 1.1 ms
All values are given as mean ± SEM. Ventricular action potential durations at 50 
and 70% repolarization showed no differences between treatment groups 
(unpublished data).
aA signifi  cant difference (P < 0.05).
Table I. General physical and gross pathological parameters in 
mice treated with G-CSF/SCF or placebo (controls)
G-CSF/SCF Controls P-value
Age (weeks) 24 ± 1.8 26 ± 2.1 0.49
Weight (g) 35.6 ± 1.4 35.3 ± 1.6 0.9
Heart rate during 
 echo  cardiography (b/min)
434 ± 26 378 ± 26 0.14
Stroke Volume (μl) 32.5 ± 2.1 28.7 ± 1.7 0.17
Infarct length
 (mm;  n = 10 per group)
5.4 ± 0.4 5.4 ± 0.2 0.82
Infarct width
 (mm;  n = 9 per group)
4.8 ± 0.3 4.7 ± 0.4 0.71
Infarct area (length × width) 26.8 ± 3.2 25.0 ± 2.2 0.65
Left atrial diameter (mm) 2.3 ± 0.2 2.2 ± 0.2 0.58
LVOT diameter 1.1 ± 0.02 1.1 ± 0.02 0.65
All values are given as mean ± SEM. Functional parameters are assessed by 
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animals is in the range observed in nonsplenectomized ani-
mals (29), the boost in the proportion of neutrophils is less 
pronounced in nonsplenectomized animals (not depicted). 
Nevertheless, Adachi et al. (30), who also did not use sple-
nectomized animals for their experiments, reported an in-
creased infi  ltration of BM-derived side population cells into 
the G-SCF–treated infarcted heart. Together with recent 
data (20) about the secretion by BM-derived mesenchymal 
stem cells of so far unknown paracrine factor(s), capable of 
reducing the infarct size in a rat model of permanent cor-
onary artery occlusion, their results demonstrate that the 
question of the relative contribution of direct and para-
crine eff  ects to the therapeutic action of G-CSF is not defi  -
nitely answered.
Figure 4.  (A) Examples of monomorphic (top) and polymorphic 
(bottom) ventricular tachycardia induced by programmed stimula-
tion using a single (top) or two (bottom) extra stimuli. Shown are 
three simultaneously recorded MAP recordings obtained from the right 
ventricular (MAP RV), left ventricular septal (MAP LVsept), and left ventric-
ular free wall (MAP LVfree) epicardium. In the lower panel, the left ven-
tricular free wall is recorded from the infarcted area and shows the typical 
alterations found in infarcted scar tissue: loss of the action potential dome 
and slow activation. Asterisks indicate stimulus artifacts in the right ven-
tricular MAP recording. (B) Number of hearts with induced ventricular 
tachycardias (>10 consecutive premature ventricular activations) as a 
function of the number of extra stimuli (S2, fi  rst extra stimulus; S3, second 
extra stimulus) shown for hearts with G-CSF/SCF (black bars) and hearts 
from non-G-CSF/SCF control animals (gray bars). Ventricular tachycardia 
induction was less likely in G-CSF/SCF-treated hearts than in controls. 
(C) Left: Representative immunohistological sections of normal myocar-
dium (top panels) and the border zone of the infarction (bottom panels) in 
untreated (left panels) and G-CSF/SCF-treated (right panels) hearts. Bright 
red immunofl  uorescence, connexin43; dark red, autofl  uorescence of myo-
cytes; green, immunofl  uorescence detection of a fi  brous tissue marker (rat 
anti-reticular fi  broblast antibody; refer to Materials and methods, and see 
supplemental Materials and methods for a 3D visualization of connexin43 
localization in the intercellular connections). Right (diagram): Mean con-
nexin43 expression measured as connexin43+ area in relation to the whole 
area of myocardial tissue in the fi  eld of view. Connexin43 expression was 
markedly reduced in the border zone of the myocardial infarction. G-CSF/
SCF increased connexin43 expression in the border zone without affecting 
connexin43 expression in normal myocardium.JEM VOL. 203, January 23, 2006  93
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Our results regarding G-CSFR expression are in agree-
ment with Harada et al. (14) as well as Schneider et al. (31) 
and suggest that the infarcted myocardium is sensitized for 
direct eff  ects of G-CSF by an increased expression of the 
G-CSFR. Together with the parallel increase of local G-CSF 
expression after myocardial infarction (Fig. 2 B), these data 
suggest the existence of an endogenous mechanism of G-CSF 
signaling activation potentially mediating cardioprotective 
eff  ects. Similar results were obtained in a model of brain 
  infarction (31). However, in view of the twofold-increased 
homing of BM-derived cells, they also do not allow to favor 
one of the explanations (paracrine vs. direct eff  ects) but leave 
the alternative open that both mechanisms act in parallel. 
Nevertheless, the recent observation of a rise of G-CSF con-
centration in the blood accompanied by an increase of pe-
ripheral CD34+ cells (endothelial progenitor cells) after acute 
myocardial infarction in humans (32) allows us to speculate 
that myocardial damage by itself leads to the activation of an 
endogenous BM mobilization mechanism, possibly enhanc-
ing the recruitment of BM-derived cells from the blood.
Improvement of cardiac output
Concordant with results from some (33), but not all (14), 
groups, we found no change in infarct size after G-CSF/SCF 
treatment. In addition, we did not fi  nd evidence for the 
generation of new myocardium after G-CSF/SCF treatment. 
Cardiomyocyte hypertrophy in the border zone of the in-
farction was, however, increased in G-CSF/SCF-treated 
hearts. Increased binding of G-CSF to its receptor on cardio-
myocytes activates the Akt (34, 35) as well as the Jak/STAT 
Figure 5.  Infl  uence of G-CSF/SCF on arterialization and cardio-
myocyte diameter. (A) Increased arterialization of the area of infarction, 
including the border zone, in G-CSF/SCF-treated hearts. Left: In situ iden-
tifi  cation of arterial vessels, visualized by α-smooth muscle actin staining 
(red fl  uorescence) in the non-infarcted (left panels) and infarcted areas 
plus the border zone (right panels) of untreated (top panels) and G-CSF/
SCF-treated hearts (bottom panels). Right: Quantitative analysis of arteri-
alization. *, statistical signifi  cance of difference (P < 0.05); #, a p-value 
determined by performing a nonparametric test (Wilcoxon signed rank 
test) because a normality test failed. Performing the corresponding para-
metric test would lead to P < 0.05. (B) G-CSF/SCF increases cardiomyo-
cyte diameter in the border zone of the infarction. Left: In situ detection 
of cardiomyocyte diameter in the non-infarcted areas (left panels) and in 
the border zone of infarction (right panels) of untreated (top panels) and 
G-CSF/SCF-treated hearts (bottom panels). Red fl  uorescence, cardiomyo-
cyte boundaries; DAPI staining, nuclei; green autofl  uorescence, cardio-
myocytes. Right: Quantitative analysis. There was no difference in normal 
myocardium between controls and G-CSF/SCF-treated hearts in normal 
myocardium, but cardiomyocyte diameter was increased in G-CSF/SCF-
treated hearts in the border zone of the infarction.94  G-CSF/SCF REDUCES INDUCIBLE ARRHYTHMIAS IN THE INFARCTED HEART | Kuhlmann et al.
pathway (14, 36), which are both known to impart hypertro-
phic signaling in cardiomyocytes. For the Akt pathway, it has 
also been demonstrated that its transgene-mediated, constitu-
tive activation in mouse cardiomyocytes improves their con-
tractile function in vitro as well as in vivo (37).
The increased vascularization in the border zone of the 
infarction (Fig. 5 A) might have also contributed to the im-
proved cardiac output by enabling increased supply of oxy-
gen and nutrients. Angiogenesis might be at least in part 
induced by direct eff  ects of G-CSF, indicated by distinct im-
munolocalization of G-CSFR in vessel wall cells 1 d after in-
duction of myocardial infarction. This fi  nding is in accordance 
with Harada et al. (14), who detected G-CSFR expression 
in endothelial cells, and with Chen et al. (38), who demon-
strated that G-CSF induces proliferation of vascular smooth 
muscle cells. Activation of the Akt as well as the Jak/STAT 
pathway by the binding of G-CSF to its receptor also might 
have been responsible for the enhanced induction of arte-
riogenesis in the G-CSF/SCF-treated hearts as suggested by 
work of Iwanaga et al. (39) and Harada et al. (14).
Lack of proarrhythmic effects of G-CSF/SCF
Despite the homing of a large number of BM-derived cells 
into the border zone of myocardial infarction (up to 30% of 
all nucleated cells), a dedicated protocol to provoke afterde-
polarizations and ventricular arrhythmias did not provoke 
afterdepolarizations or spontaneous ventricular tachycardias 
in G-CSF/SCF-treated hearts. The lack of diff  erentiation 
into myocytes of the majority of BM-derived cells, observed 
by us and others (17–19, 40), and consideration of the elec-
trotonic attenuation of abnormal electrical behavior of a sin-
gle cell when it is integrated into the myocardial syncytium, 
can explain that we did not fi  nd afterdepolarizations in the 
intact heart.
Reduced inducibility of ventricular arrhythmias
G-CSF/SCF-treated hearts had less inducible ventricular ar-
rhythmias during programmed ventricular stimulation than 
controls (Fig. 4 B). Slow conduction due to decreased inter-
cellular coupling in the border zone of a healed myocardial 
infarction is the pivotal factor for reentrant ventricular tachy-
cardias in this setting (26, 41, 42). Reentry due to slow zigzag 
conduction in the border zone of an infarction is mainly 
caused by a dramatic decrease in expression of gap junctional 
proteins, specifi  cally in connexin43 (26, 43). Indeed, a reduc-
tion of connexin43 expression by  90% is suffi   cient to en-
hance inducibility of ventricular tachycardias in transgenic 
mice (44). A comparable (90%) reduction of connexin43 ex-
pression was found in cardiomyocytes in the border zone of 
the infarction in the absence of G-CSF/SCF treatment (Fig. 
4 C). G-CSF/SCF partially reversed the down-regulation of 
connexin43 expression (Fig. 4 C) by increasing connexin43 
levels in the border zone of the infarction to  25% of nor-
mal   expression. This level of connexin expression is suffi   -
cient  to maintain almost normal conduction velocities (44) 
and can explain why G-CSF/SCF-treated hearts were pro-
tected against induction of ventricular tachyarrhythmias in 
this study.
This study examined the midterm electrophysiological 
eff  ects of G-CSF/SCF into the infarcted myocardium. Ar-
rhythmic events, including sudden arrhythmic death, may 
occur late after myocardial infarction, and current revascular-
ization therapies during acute myocardial infarction usually 
limit infarct size in the clinical setting. The G-CSF/SCF 
treatment protocol was chosen here in agreement with the 
pioneering work by Orlic et al. (10) to allow for comparison 
of our data with those published by this group. Further stud-
ies are needed to establish a protocol for BM mobilization 
that is clinically applicable, i.e., where treatment begins dur-
ing the acute phase of a myocardial infarction.
In summary, our data suggest that G-CSF/SCF has ben-
efi  cial functional hemodynamic, electrophysiological, and 
microstructural eff  ects in the absence of formation of new 
myocardium from BM-derived cells.
MATERIALS AND METHODS
Animals. 114 mice, which were 58 CD1 outbred mice (Charles River 
Deutschland GmbH; body weight 23–30 g at the day of myocardial infarc-
tion) and 56 female C57BL/6 inbred mice (Charles River Deutschland 
GmbH; body weight 20–26 g at the day of BMT), were studied. C57BL/6 
mice served as hosts for BM transplantation from EGFP-expressing trans-
genic donor mice (also C57BL/6 background; reference 45). These mice 
were used to analyze myocardial homing of BM-derived cells. All experi-
ments were performed in accordance with the German Law on the Care and 
Use of Laboratory Animals and were approved by the local Institutional 
  Review Board.
Transplantation of EGFP-expressing BM-derived cells and splenec-
tomy. To investigate the eff  ect of G-CSF/SCF on mobilization and myo-
cardial homing of BM-derived cells, 34 recipient mice underwent total body 
irradiation at a dose of 11 Gy (0.98 Gy/min), and intravenous infusion of 
BM (2 × 107 mononuclear cells) was harvested from EGFP-expressing mice 
the next day. The procedural details have been described previously (46). 
Blood cell chimerism determined 8 wk after BMT by FACS analysis showed 
>95% donor cells (EGFP+) in all transplanted mice. Myocardial homing of 
BM-derived cells was studied 10 wk after BMT.
With the exception of eight C57BL/6 animals only used for the analysis 
of BM mobilization in nonsplenectomized mice, all experimental animals 
were splenectomized according to a published protocol (10) at least 2 wk 
before BMT or G-CSF/SCF treatment in non-BMT animals.
G-CSF/SCF treatment and induction of myocardial infarction. Re-
combinant mouse SCF (50 µg/kg/day; R&D Systems) and recombinant hu-
man G-CSF (200 µg/kg/day; Chugai Pharma Marketing Ltd.) were injected 
subcutaneously for 6 d. Control mice received daily injections of 0.9% sa-
line. On the third day of G-CSF/SCF treatment, myocardial infarction was 
induced by ligation of the proximal LAD. To investigate basal accumulation 
of EGFP-expressing BM-derived cells in the myocardium, in 10 BMT 
  animals (5 G-CSF/SCF-treated and 5 controls) no myocardial infarction 
was induced. For additional information see the supplemental Materials 
and methods, available at http://www.jem.org/cgi/content/full/jem.
20051151/DC1.
Five G-CSF/SCF mice and four controls with EGFP-expressing BM 
(see above) were killed 24 h after induction of myocardial infarction (fourth 
day of G-CSF/SCF treatment) to determine the expression of G-CSFR. 
The hearts of all other animals were analyzed 5 wk after ligation of the LAD 
(animals with myocardial infarction) or the third day of G-CSF/SCF treat-
ment (animals without myocardial infarction).JEM VOL. 203, January 23, 2006  95
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White blood cell analysis. After 4 d of G-CSF/SCF treatment, 200 µl 
blood was obtained from the tail vein of 31 animals (15 controls and 16 
treated with G-CSF/SCF). Automatic full blood count measurements 
using the KK-21 hematology analyzer (Sysmex GmbH) were performed. 
After Pappenheim staining of blood smears, the proportion of lympho-
cytes,   neutrophils, and monocytes in at least 100 white blood cell counts 
was calculated.
Echocardiography and surface ECG recordings. Sedated mice (ket-
amine/xylazine) underwent Doppler echocardiographic studies 5 wk after 
infarction immediately before the electrophysiological study according to 
published procedures (47). For additional details, see the supplemental Ma-
terials and methods.
Electrophysiological study in isolated hearts. The heart was excised 
under general anesthesia, and the aorta was cannulated and retrogradely per-
fused using 37°C Krebs-Henseleit buff   er (in mmol/liters; NaCl 118, 
NaHCO3 24.88, KH2PO 41.18, glucose 5.55, Na-pyruvate 2, MgSO4 
0.83, CaCl2 1.8, KCl 4.7) equilibrated with a 95% oxygen/5% carbon diox-
ide gas mixture. The heart was mounted on a vertical Langendorff   apparatus 
(Hugo Sachs Electronic-Harvard Apparatus GmbH) and constantly perfused 
at 100 ± 5 mmHg perfusion pressure, corresponding to coronary fl  ow rates 
of 4 ± 1 ml/min. An octapolar mouse electrophysiologic catheter (CIBER 
MOUSE; NuMED) was placed in the right atrium and ventricle for atrial 
and ventricular pacing. A tissue bath ECG was recorded from Ag-AgCl elec-
trodes immersed in superfused sponges fl  anking the isolated heart. Three 
murine monophasic action potentials (MAPs) were continuously and simul-
taneously recorded from the right and left ventricular epicardium (23–25). 
One MAP was positioned within the border zone of the infarct to record af-
terdepolarizations. All recordings were obtained simultaneously throughout 
the experimental protocols. ECG signals were amplifi  ed and fi  ltered by an 
ECG amplifi  er at a bandwidth of 0.1 to 300 Hz (Hugo Sachs Electronic-
Harvard Apparatus GmbH). MAP signals were amplifi  ed using dedicated 
MAP amplifi  ers (Boston Scientifi  c Inc.). Additional details of the experi-
mental setup have been described previously (23–25).
After placing all catheters in a stable position, atrial pacing was performed 
at diff  erent pacing cycle lengths to measure steady-state action potential dura-
tions. To provoke ventricular arrhythmias initiated by afterdepolarizations, 
the atrioventricular node was ablated and the spontaneous ventricular rhythm 
was observed for 10 min (23, 24). Thereafter, to test the propensity to reen-
try, programmed ventricular stimulation was performed using up to two pre-
mature stimuli (S2 and S3) at diff  erent pacing cycle lengths (80–140 ms; 
reference 48). All signals were digitized at 1 or 2 KHz and stored on digital 
media for offl   ine analysis.
Histology and immunofl  uorescence. After completion of the electro-
physiologi25cal procedure, hearts were either fi  xed in Bouin’s solution and 
stained using Goldner’s Trichrom staining, or fi  xed in 3.7% formaldehyde, 
followed by dehydration in 10% sucrose solution, O.C.T. embedding, and 
cryoconservation for fl  uorescent detection of EGFP-expressing cells or im-
munofl  uorescent detection of various antigens according to an established 
protocol (49). The following primary antibodies were used: rat anti–mouse 
CD45 as a marker for blood cells (AB3088; Abcam Limited), monoclonal 
anti–troponin T as a marker of diff  erentiated cardiomyocytes (cardiac iso-
form AB-1, clone 13-11; Lab Vision), rabbit anti–rat connexin43 polyclonal 
antibodies for the detection of gap junctions (71-0700; Zytomed GmbH), 
monoclonal rat anti-reticular fi  broblast antibodies (clone ER-TR7; Novus 
Biologicals Inc.), rabbit smooth muscle anti-actin antibody for the detection 
of arteries and arterioles (RB-9010; Lab Vision Corporation), rabbit c-kit 
(SCF receptor) antibody (sc-168; Santa Cruz Biotechnology, Inc.), and rab-
bit anti–G-CSFR antibody (sc-694; Santa Cruz Biotechnology, Inc.). For 
additional information see the supplemental Materials and methods.
Sections were examined using a confocal fl  uorescence microscope (Ax-
ioplan 2 and LSM 510 Meta; Carl Zeiss MicroImaging, Inc.). Images were 
digitized and transferred to a personal computer. For quantifi  cation of diff  er-
ent cell populations, the number of EGFP+ cells and of EGFP+ cells coex-
pressing the immunohistological marker (anti-CD45 or anti–troponin T 
antibody) were counted in three randomly selected fi  elds of view at the same 
magnifi  cation (400) in the infarcted area, the border zone, and in the non-
infarcted area of the left ventricle. For quantitative analysis of connexin ex-
pression, the number of connexin43+ spots and the proportion of the 
connexin43+ area in relation to the nonfi  brotic myocardial area of the re-
spective fi  eld of view were determined on digitized images taken at high 
magnifi  cation (400) from at least two nonconsecutive slides per mouse heart 
(four control and fi  ve G-CSF/SCF-treated animals) using Adobe Photoshop 
CS (Adobe Systems GmbH) and ImageJ 1.32 imaging software (National 
Institute of Mental Health). A minimum of eight images from the border 
zone and the non-infarcted area was analyzed in each heart.
Quantitative analysis of the arterial vessel area (smooth muscle anti-ac-
tin+ area of vessels and enclosed lumina) was analyzed as described for the 
measurement of the connexin43+ area (see above). In addition, the number 
of arterial vessels per fi  eld of view as well as the diameter of each vessel per 
fi  eld of view were determined.
Histological sections immunostained for fi  broblasts/connective tissue 
were also used for short axis diameter measurement of cardiomyocytes at 
the nuclear level (100 cells per region and animal) using published meth-
ods (50) adapted for immunofl  uorescence; i.e., DAPI staining was used 
for the detection of nuclei and cardiomyocytes were identifi  ed based on 
their autofl  uorescence.
RNA isolation and real-time RT-PCR. Infarcted hearts of male CD1 
mice at diff  erent time points after surgery (30 min, n = 2; 1 h, n = 3; 4 h, 
n = 3; 24 h, n = 2; 1wk, n = 2; 6 wk, n = 3) were explanted and the area 
of infarction, including its border zone, was separated from the non-in-
farcted myocardial tissue. Ventricular tissues of seven explanted hearts of un-
treated male CD1 mice served as controls.
Isolation of RNA from mouse heart tissue was performed using the 
RNeasy Fibrous Tissue Mini kit (QIAGEN) according to the manufactur-
er’s protocol. Reverse transcription was performed using the ImProm-IITM 
Reverse Transcription System (Promega) according to the manufacturer’s 
protocol. cDNA samples reverse transcribed from RNAs were analyzed by 
quantitative RT-PCR using primers (see the supplemental Materials and 
methods) purchased from MWG-BIOTECH AG. Quantitative RT-PCR 
was performed using SYBR Green Reaction Mix (Eurogentec) on an ABI 
PRISM 7900HT Detection System (Applied Biosystems). Each sample was 
run in duplicate. The expression of each gene within the diff  erent tissue 
samples was quantifi  ed relative to cyclophilin A expression according to the 
Sequence Detector User Bulletin 2 (Applied Biosystems).
Statistics. All procedures and analyses (functional and histological) were 
performed by a blinded experimenter with respect to treatment group 
(G-CSF/SCF vs. control). Depending on the existence of equal variances 
and normal distribution of data, treatment groups were compared using an 
unpaired t test and one-way ANOVA, respectively, or the corresponding 
nonparametric test procedures (Mann-Whitney U test and Kruskal-Wallis 
test). A chi-square test and log rank test were used to compare nominal pa-
rameters (e.g., inducibility of arrhythmias or mortality).
Online supplemental material. QuickTime videos (Videos S1–S4) pre-
senting 3D-animated sequences of confocal scans of myocardial sections im-
munolabeled for connexin43/connective tissue (same scale as in Fig. 4 C) 
and supplemental Materials and methods are available at http://www.jem.
org/cgi/content/full/jem.20051151/DC1.
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